Literature DB >> 30777654

Neuropathological and genetic characteristics of a post-mortem series of cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Jakob's disease.

H Geut1, L J M Vergouw2, Y Galis3, A Ingrassia3, F J de Jong2, M Quadri4, V Bonifati4, A W Lemstra5, A J M Rozemuller6, W D J van de Berg3.   

Abstract

INTRODUCTION: The disease course of dementia with Lewy bodies (DLB) can be rapidly progressive, clinically resembling Creutzfeldt-Jakob's disease (CJD). To better understand factors contributing to this rapidly progressive disease course, we describe load and distribution of neuropathology, and the presence of possible disease-associated genetic defects in a post-mortem series of DLB cases clinically suspected of CJD.
METHODS: We included pathologically confirmed DLB cases with a disease duration of 3.5 years or less from the Dutch Surveillance Center for Prion Diseases, collected between 1998 and 2014. Lewy body disease (LBD) and Alzheimer's disease (AD)-related pathology were staged and semi-quantitatively scored in selected brain regions. Whole exome sequencing analysis of known disease-associated genes, copy number analysis, APOE ε genotyping and C9orf72 repeat expansion analysis were performed to identify defects in genes with a well-established involvement in Parkinson's disease or AD.
RESULTS: Diffuse LBD was present in nine cases, transitional LBD in six cases and brainstem-predominant LBD in one case. Neocortical alpha-synuclein load was significantly higher in cases with intermediate-to-high than in cases with low-to-none AD-related pathology (p = 0.007). We found two GBA variants (p.D140H and p.E326K) in one patient and two heterozygous rare variants of unknown significance in SORL1 in two patients.
CONCLUSION: A high load of neocortical alpha-synuclein pathology was present in most, but not all DLB cases. Additional burden from presence of concomitant pathologies, synergistic effects and specific genetic defects in the known disease-associated genes may have contributed to the rapid disease progression.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein pathology; Autopsy; GBA; Rapidly progressive dementia

Mesh:

Substances:

Year:  2019        PMID: 30777654     DOI: 10.1016/j.parkreldis.2019.02.011

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  8 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 2.  Rapidly progressive dementias - aetiologies, diagnosis and management.

Authors:  Peter Hermann; Inga Zerr
Journal:  Nat Rev Neurol       Date:  2022-05-04       Impact factor: 44.711

Review 3.  Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.

Authors:  David G Coughlin; Howard I Hurtig; David J Irwin
Journal:  Mov Disord       Date:  2019-10-29       Impact factor: 10.338

Review 4.  Proteostatic imbalance and protein spreading in amyotrophic lateral sclerosis.

Authors:  Maria Elena Cicardi; Lara Marrone; Mimoun Azzouz; Davide Trotti
Journal:  EMBO J       Date:  2021-03-31       Impact factor: 11.598

Review 5.  Genetic architecture of common non-Alzheimer's disease dementias.

Authors:  Rita Guerreiro; Elizabeth Gibbons; Miguel Tábuas-Pereira; Celia Kun-Rodrigues; Gustavo C Santo; Jose Bras
Journal:  Neurobiol Dis       Date:  2020-05-19       Impact factor: 5.996

6.  Parkinson's disease with a typical clinical course of 17 years overlapped by Creutzfeldt-Jakob disease: an autopsy case report.

Authors:  Shin-Ichiro Kubo; Tomoyasu Matsubara; Takeshi Taguchi; Renpei Sengoku; Atsuko Takeuchi; Yuko Saito
Journal:  BMC Neurol       Date:  2021-12-10       Impact factor: 2.474

Review 7.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26

8.  SORL1 mutation in a Greek family with Parkinson's disease and dementia.

Authors:  Georgia Xiromerisiou; Thomas Bourinaris; Henry Houlden; Patrick A Lewis; Konstantin Senkevich; Monia Hammer; Monica Federoff; Alaa Khan; Cleanthe Spanaki; Georgios M Hadjigeorgiou; Sevasti Bonstanjopoulou; Liana Fidani; Aleksey Ermolaev; Ziv Gan-Or; Andrew Singleton; Jana Vandrovcova; John Hardy
Journal:  Ann Clin Transl Neurol       Date:  2021-09-10       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.